Same Indication

Ipilimumab vs Metformin

Ipilimumab vs Metformin: Overview

This comparison examines the pharmacological differences between Ipilimumab and Metformin.

Mechanism of Action

Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.

Metformin: Activates AMP-activated protein kinase, decreasing hepatic glucose production.

Pharmacokinetics

Half-life: Ipilimumab — 14.7 days; Metformin — 4-9 hours.

Chemical Properties

Molecular Formula: Metformin — C4H11N5.

Molecular Weight: Metformin — 129.1640 g/mol.

Type: Ipilimumab — Antibody; Metformin — Small molecule.